AKT1 and neoplasm: In line, a recent study by Li et al. demonstrated that co-targeting EGFR (upstream of PI3K/AKT) and NF-κB pathways led to a superior inhibition of cell survival and xenograph tumor growth, when compared to targeting either pathway alone (49).